Posted: March 23, 2014 at 8:44 pm
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson http://www.docereclinics.com.
By: Harry Adelson, N.D.
Here is the original post:
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson - Video
Posted: March 23, 2014 at 8:44 pm
Before undergoing regenerative stem cell therapy in November, a 5-year-old Newfoundland named Bella had been on medication for most of her life.
A congenital issue that affects about 25 percent of her breed left 138-pound Bella walking with a limp and unable to keep up with her brother, Ollie, on their twice-daily walks at Polipoli Spring State Recreation Area, said her owner, Art Terry of Kula.
"We were at the point of being hopeless," he said. "She'd been progressing to where she couldn't walk anymore. I couldn't take her to the park. She used to hobble around the house."
Bella, a 138-pound Newfoundland, and her owner, Art Terry, wait outside the Animal Care Hospital and Wellness Center in Kula just before she underwent stem cell therapy in November.
Animal Care Hospital and Wellness Center photo
Veterinary head technician Michelle James processes fat cells for stem cell activation with veterinarian Dennis Brown at the Animal Care Hospital and Wellness Center in Kula.
Animal Care Hospital and Wellness Center photo
Veterinary technician Samara Phillips (left) monitors anesthesia with veterinary head technician Michelle James and Dr. Dennis Brown during Bellas stem cell therapy procedure.
Animal Care Hospital and Wellness Center photo
Since the stem cell therapy, "you can't believe it's the same dog," Terry said. "I had to stop her chasing cars a couple of times at Polipoli park."
See the article here:
Kula veterinarian offering in-house stem cell therapy
Posted: March 23, 2014 at 8:44 am
Should stem cell therapy be used in DLBCL?
By: Lymphoma Hub
Read this article:
Should stem cell therapy be used in DLBCL? - Video
Posted: March 23, 2014 at 8:44 am
The Philippines is the biggest market for the popular, if highly controversial, alternative treatment in Germany called fresh-cell therapy (FCT). Fresh cells derived from the fetus of an unborn lamb are injected into patients, and are said to cure a large number of illnesses.
Despite the high cost of the treatment, wealthy Filipinos are undeterred, and typically arrive in droves in a sleepy town outside Frankfurt, their hopes of being cured or rejuvenated pinned on the life of every donor sheep.
Given its renown, its no surprise that questions about the efficacy and safety of FCT has been the subject of discussions among health professionals. There have also been rumors of deaths after FCT.
The proponents of FCT in Germany, however, claim that all talk about patient deaths and questionable safety standards are unfounded, and an uncouth effort to discredit FCT so that the same medical professionals here could promote stem-cell therapy, which is allowed in the country. They deny the rumors of deaths and challenge their accusers to show proof. They also maintain that FCT is a decades-old, legitimate and safe naturopathic treatment.
Theres also a rivalry in Edenkoben between the famous clinic Villa Medica and the breakaway practice of Dr. Robert Janson-Mller, who used to work at the same clinic.
Dr. Mller now administers FCT in a hotel, which doubles as his clinic. This gave rise to talks questioning the standards of a practice that is done in a hotel, not a hospital. Some accounts also say that there have been Filipino patients fooled into believing they were bound for Villa Medica, only to find themselves in Dr. Mullers hotel.
Inquirer Lifestyle visits the two rival clinics in Germany, and we experience firsthand what FCT is all about.
Follow Us
Recent Stories:
Tags: Dr. Robert Janson-Mller , Frankfurt , fresh cell therapy , Stem Cell Therapy , Villa Medica
More here:
The furor over fresh-cell therapy (which is NOT stem cell therapy)
Posted: March 22, 2014 at 6:43 pm
Interview with David Schaffer on stem cell research
The Daily Californian sits down with David Schaffer, director of the Berkeley Stem Cell Center at UC Berkeley, for an in-depth discussion on his research.
By: thedailycal
See original here:
Interview with David Schaffer on stem cell research - Video
Posted: March 22, 2014 at 4:46 pm
PUBLIC RELEASE DATE:
20-Mar-2014
Contact: Matthew Inlay minlay@uci.edu 949-824-8226 University of California - Irvine
Irvine, Calif., March 20, 2014 Hematopoietic stem cells are now routinely used to treat patients with cancers and other disorders of the blood and immune systems, but researchers knew little about the progenitor cells that give rise to them during embryonic development.
In a study published April 8 in Stem Cell Reports, Matthew Inlay of the Sue & Bill Gross Stem Cell Research Center and Stanford University colleagues created novel cell assays that identified the earliest arising HSC precursors based on their ability to generate all major blood cell types (red blood cells, platelets and immune cells).
This discovery of very early differentiating blood cells, Inlay said, may be very beneficial for the creation of HSC lines for clinical treatments.
"The hope is that by defining a set of markers that will allow us to make purer, cleaner populations of these precursor cells, we'll be able to reveal the key molecular events that lead to the emergence of the first HSCs in development. This could give us a step-by-step guide for creating these cells in a dish from pluripotent stem cell lines" added Inlay, who is an assistant professor of molecular biology & biochemistry at UC Irvine and conducted the study while a postdoctoral researcher in the Irving Weissman lab in the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.
###
The work was performed in collaboration with Thomas Serwold, now an assistant professor in the Joslin Diabetes Center at Harvard Medical School.
The research reported in this article was supported by the National Institutes of Health (grants 5 T32 AI07290, R01HL058770, R01CA86085 and U01HL09999), the California Institute for Stem Cell Research (grants T1-00001, RT2-02060 to I.L.W.), the Harvard Stem Cell Institute, the Siebel Stem Cell Institute, the Thomas and Stacey Siebel Foundation, and the Virginia and D.K. Ludwig Fund for Cancer Research.
Read the rest here:
Stem cell study finds source of earliest blood cells during development
Posted: March 22, 2014 at 4:41 pm
Poway, California (PRWEB) March 21, 2014
Ruby, a 10 year old Border Collie mix from Breckenridge, Colorado, has found relief from the pain of arthritis with stem cell therapy by Vet-Stem, Inc. Rubys owners came to Jamie Gaynor, DVM at Frisco Animal Hospital for a second opinion after being told Ruby would need a total hip replacement to relieve her constant pain and discomfort. Her quality of life had diminished so rapidly they feared losing her.
Dr. Gaynor began performing stem cell therapy by Vet-Stem for pets in 2006, in Colorado Springs. Paralleling his specialties in pain management, he has now helped well over one hundred pets in the state of Colorado, and ones that traveled just to have his expertise. His credentials and experience made Dr. Gaynor the perfect fit for helping Rubys worsening bilateral hip arthritis despite aggressive drug therapy. Ruby would become Dr. Gaynors first stem cell therapy case at Frisco Animal Hospital; Summit Countys first and oldest animal hospital.
Ruby was in constant pain and discomfort. She had to be carried up stairs and could not go on car rides; her second favorite thing to do. Her quality of life was diminishing rapidly, and we thought we were losing her, explained Rubys owners.
Rubys stem cell procedure consisted of a small fatty tissue collection, which was sent overnight to Vet-Stems lab in California for processing. Once Rubys fat was processed, and stem cells were extracted, fresh doses of her stem cells were sent overnight back to Dr. Gaynor in injectable doses. Within 48hrs of collecting a fat sample from Ruby, Dr. Gaynor was able to inject stem cells into each of her arthritic, painful hips, making Ruby his first stem cell therapy case in Summit County.
Dr. Gaynor and Rubys owners were both pleased with the successful outcome of the procedure, and had the opportunity to share during her 30 day recheck. Ruby is back! She has regained her playfulness, sassy, bossy, collie attitude. She has resumed going for car rides and can stand up and stabilize herself. She jumps out of the car without hesitation. She ascends and descends the stairs like she used to, her owners remarked about Rubys physical performance.
Her entire disposition and expressions are so animated and relaxed. I forgot how she used to smile, hold her ears up, and have endless energy. She is definitely out of pain, and her mobility is at 80%! The best part is, that she continues to heal and get stronger each week. This procedure is hands down the most effective, least traumatic therapy available, especially for the older dog, Rubys owners expressed.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
See the original post here:
Stem Cell Therapy for Pets in Summit County Colorado Proves to Be a Success for Local Dog Suffering from Pain
Posted: March 22, 2014 at 4:41 pm
In India, stem cell biz may touch $8 b by 2015
Mumbai, March 21:
Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be an ideal supplement for existing medical treatments, he added.
Cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
We have a research unit in Malaysia that is conducting research on stem cells, Hamied said while speaking about Stempeutics Research with which it has an alliance. The Manipal Group-promoted Stempeutics is developing stem cell-based medicinal products with facilities in Kuala Lumpur (Malaysia) and Bangalore.
We are partners in the Bangalore company, he said. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market, he added.
Poised to reach an estimated $88.3 billion by 2015, the global stem cells market has been growing at a compounded annual growth rate of 14.8 per cent, driven by the increasing demand of stem cell therapy.
In India, the stem cell business is expected to touch $8 billion (48,880 crore today) by 2015. With three phase II clinical trials in progress in India for critical limb Ischemia (meaning restriction in blood supply to tissues), osteoarthritis and liver cirrhosis Stempeutics aims to bring the first product into the Indian and Malaysian markets by 2015.
Under the alliance, Cipla has invested over 50 crore in Stempeutics, with a focus on research of stem cell-based products, and has done something similar in China, where it has streamlined its investments towards its core business. The drug-maker recently exited a significant part of its investment in its Chinese partner Desano Holdings.
Despite the lack of legislation and awareness, besides quality and ethical issues that have deterred growth of the stem cell therapy business in India, the country remains the top priority for the Mumbai-based drug-maker, the Cipla Chairman told Business Line.
Read more:
Cipla bets big on cell therapy
Posted: March 22, 2014 at 12:49 am
Contact Information
Available for logged-in reporters only
Note: A high-resolution photo to accompany this release is available at http://www.news.wisc.edu/newsphotos/masatoshiSuzuki_13.html
Newswise MADISON, Wis. As stem cells continue their gradual transition from the lab to the clinic, a research group at the University of Wisconsin-Madison has discovered a new way to make large concentrations of skeletal muscle cells and muscle progenitors from human stem cells.
The new method, described in the journal Stem Cells Translational Medicine, could be used to generate large numbers of muscle cells and muscle progenitors directly from human pluripotent stem cells. These stem cells, such as embryonic (ES) or induced pluripotent stem (iPS) cells, can be made into virtually any adult cell in the body.
Adapting a method previously used to make brain cells, Masatoshi Suzuki, an assistant professor of comparative biosciences in the School of Veterinary Medicine, has directed those universal stem cells to become both adult muscle cells and muscle progenitors.
Importantly, the new technique grows the pluripotent stem cells as floating spheres in high concentrations of two growth factors, fibroblast growth factor-2 and epidermal growth factor. These growth factors "urge" the stem cells to become muscle cells.
"Researchers have been looking for an easy way to efficiently differentiate stem cells into muscle cells that would be allowable in the clinic," says Suzuki. The novelty of this technique is that it generates a larger number of muscle stem cells without using genetic modification, which is required by existing methods for making muscle cells.
"Many other protocols have been used to enhance the number of cells that go to a muscle fate," says co-author Jonathan Van Dyke, a post-doctoral fellow in Suzukis laboratory. "But what's exciting about the new protocol is that we avoid some techniques that would prohibit clinical applications. We think this new method has great promise for alleviating human suffering."
Last year, Suzuki demonstrated that transplants of another type of human stem cells somewhat improved survival and muscle function in rats that model amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS destroys nerves and causes a loss of muscle control. The muscle progenitors generated with Suzukis new method could potentially play a similar role but with enhanced effect.
Read more:
A New Way to Make Muscle Cells From Human Stem Cells
Posted: March 22, 2014 at 12:49 am
London, March 21 (IANS): In a major breakthrough, a team of scientists has developed a method to generate human induced pluripotent stem cells (hiPSCs) from just a drop of finger-pricked blood.
As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for scientific research.
Earlier methods to generate hiPSCs generally required large quantities of blood.
The new method developed by scientists at Institute of Molecular and Cell Biology (IMCB), Singapore also enables donors to collect their own blood samples which they can then send to a laboratory for further processing.
The do it yourself (DIY) finger-prick technique is the worlds first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency.
It all began when we wondered if we could reduce the volume of blood used for (genetic) reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it, said Loh Yuin Han Jonathan, principal investigator at IMCB.
Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests, Jonathan said.
The accessibility of the new technique is further enhanced with a DIY sample collection approach.
The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.
By integrating it with the hiPSC bank initiatives, the finger-prick technique has paved the way for establishing diverse and fully characterised hiPSC banking for stem cell research.
Read the rest here:
Stem cells generated from just blood!
